Medical - Care Facilities
Compare Stocks
2 / 10Stock Comparison
PNTG vs SGRY
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Care Facilities
PNTG vs SGRY — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Care Facilities | Medical - Care Facilities |
| Market Cap | $1.13B | $1.89B |
| Revenue (TTM) | $1.02B | $3.34B |
| Net Income (TTM) | $30M | $-76M |
| Gross Margin | 11.1% | 22.8% |
| Operating Margin | 5.6% | 11.8% |
| Forward P/E | 24.6x | 38.7x |
| Total Debt | $453M | $4.02B |
| Cash & Equiv. | $17M | $240M |
PNTG vs SGRY — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| The Pennant Group, … (PNTG) | 100 | 127.6 | +27.6% |
| Surgery Partners, I… (SGRY) | 100 | 108.8 | +8.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: PNTG vs SGRY
Each card shows where this stock fits in a portfolio — not just who wins on paper.
PNTG carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 1 yrs, beta 0.79
- Rev growth 36.3%, EPS growth 18.3%, 3Y rev CAGR 26.0%
- 115.6% 10Y total return vs SGRY's 4.9%
In this particular matchup, SGRY is outpaced on most metrics by others in the set.
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 36.3% revenue growth vs SGRY's 6.2% | |
| Value | Lower P/E (24.6x vs 38.7x) | |
| Quality / Margins | 3.0% margin vs SGRY's -2.3% | |
| Stability / Safety | Beta 0.79 vs SGRY's 1.04 | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +21.2% vs SGRY's -36.6% | |
| Efficiency (ROA) | 3.5% ROA vs SGRY's -0.9%, ROIC 5.6% vs 4.1% |
PNTG vs SGRY — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
PNTG vs SGRY — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
Evenly matched — PNTG and SGRY each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
SGRY is the larger business by revenue, generating $3.3B annually — 3.3x PNTG's $1.0B. PNTG is the more profitable business, keeping 3.0% of every revenue dollar as net income compared to SGRY's -2.3%. On growth, PNTG holds the edge at +36.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $1.0B | $3.3B |
| EBITDAEarnings before interest/tax | $66M | $572M |
| Net IncomeAfter-tax profit | $30M | -$76M |
| Free Cash FlowCash after capex | $47M | $208M |
| Gross MarginGross profit ÷ Revenue | +11.1% | +22.8% |
| Operating MarginEBIT ÷ Revenue | +5.6% | +11.8% |
| Net MarginNet income ÷ Revenue | +3.0% | -2.3% |
| FCF MarginFCF ÷ Revenue | +4.6% | +6.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | +36.0% | +4.5% |
| EPS Growth (YoY)Latest quarter vs prior year | +9.1% | +6.7% |
Valuation Metrics
SGRY leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
On an enterprise value basis, SGRY's 10.0x EV/EBITDA is more attractive than PNTG's 26.1x.
| Metric | ||
|---|---|---|
| Market CapShares × price | $1.1B | $1.9B |
| Enterprise ValueMkt cap + debt − cash | $1.6B | $5.7B |
| Trailing P/EPrice ÷ TTM EPS | 38.73x | -23.92x |
| Forward P/EPrice ÷ next-FY EPS est. | 24.55x | 38.73x |
| PEG RatioP/E ÷ EPS growth rate | 3.85x | — |
| EV / EBITDAEnterprise value multiple | 26.12x | 10.03x |
| Price / SalesMarket cap ÷ Revenue | 1.19x | 0.57x |
| Price / BookPrice ÷ Book value/share | 3.07x | 0.53x |
| Price / FCFMarket cap ÷ FCF | 42.94x | 9.65x |
Profitability & Efficiency
PNTG leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
PNTG delivers a 8.4% return on equity — every $100 of shareholder capital generates $8 in annual profit, vs $-2 for SGRY. SGRY carries lower financial leverage with a 1.14x debt-to-equity ratio, signaling a more conservative balance sheet compared to PNTG's 1.21x. On the Piotroski fundamental quality scale (0–9), SGRY scores 5/9 vs PNTG's 3/9, reflecting solid financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | +8.4% | -2.4% |
| ROA (TTM)Return on assets | +3.5% | -0.9% |
| ROICReturn on invested capital | +5.6% | +4.1% |
| ROCEReturn on capital employed | +7.3% | +5.2% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 5 |
| Debt / EquityFinancial leverage | 1.21x | 1.14x |
| Net DebtTotal debt minus cash | $436M | $3.8B |
| Cash & Equiv.Liquid assets | $17M | $240M |
| Total DebtShort + long-term debt | $453M | $4.0B |
| Interest CoverageEBIT ÷ Interest expense | 16.52x | 1.35x |
Total Returns (Dividends Reinvested)
PNTG leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in PNTG five years ago would be worth $8,279 today (with dividends reinvested), compared to $2,808 for SGRY. Over the past 12 months, PNTG leads with a +21.2% total return vs SGRY's -36.6%. The 3-year compound annual growth rate (CAGR) favors PNTG at 40.4% vs SGRY's -25.3% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | +16.9% | -4.4% |
| 1-Year ReturnPast 12 months | +21.2% | -36.6% |
| 3-Year ReturnCumulative with dividends | +176.9% | -58.4% |
| 5-Year ReturnCumulative with dividends | -17.2% | -71.9% |
| 10-Year ReturnCumulative with dividends | +115.6% | +4.9% |
| CAGR (3Y)Annualised 3-year return | +40.4% | -25.3% |
Risk & Volatility
PNTG leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
PNTG is the less volatile stock with a 0.79 beta — it tends to amplify market swings less than SGRY's 1.04 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PNTG currently trades 92.9% from its 52-week high vs SGRY's 60.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.79x | 1.04x |
| 52-Week HighHighest price in past year | $35.00 | $24.18 |
| 52-Week LowLowest price in past year | $21.73 | $11.41 |
| % of 52W HighCurrent price vs 52-week peak | +92.9% | +60.3% |
| RSI (14)Momentum oscillator 0–100 | 55.5 | 59.0 |
| Avg Volume (50D)Average daily shares traded | 240K | 1.6M |
Analyst Outlook
PNTG leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Wall Street rates PNTG as "Buy" and SGRY as "Buy". Consensus price targets imply 27.5% upside for SGRY (target: $19) vs 19.9% for PNTG (target: $39).
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $39.00 | $18.60 |
| # AnalystsCovering analysts | 7 | 22 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 1 | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
PNTG leads in 4 of 6 categories (Profitability & Efficiency, Total Returns). SGRY leads in 1 (Valuation Metrics). 1 tied.
PNTG vs SGRY: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is PNTG or SGRY a better buy right now?
For growth investors, The Pennant Group, Inc.
(PNTG) is the stronger pick with 36. 3% revenue growth year-over-year, versus 6. 2% for Surgery Partners, Inc. (SGRY). The Pennant Group, Inc. (PNTG) offers the better valuation at 38. 7x trailing P/E (24. 6x forward), making it the more compelling value choice. Analysts rate The Pennant Group, Inc. (PNTG) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — PNTG or SGRY?
On forward P/E, The Pennant Group, Inc.
is actually cheaper at 24. 6x.
03Which is the better long-term investment — PNTG or SGRY?
Over the past 5 years, The Pennant Group, Inc.
(PNTG) delivered a total return of -17. 2%, compared to -71. 9% for Surgery Partners, Inc. (SGRY). Over 10 years, the gap is even starker: PNTG returned +115. 6% versus SGRY's +4. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — PNTG or SGRY?
By beta (market sensitivity over 5 years), The Pennant Group, Inc.
(PNTG) is the lower-risk stock at 0. 79β versus Surgery Partners, Inc. 's 1. 04β — meaning SGRY is approximately 31% more volatile than PNTG relative to the S&P 500. On balance sheet safety, Surgery Partners, Inc. (SGRY) carries a lower debt/equity ratio of 114% versus 121% for The Pennant Group, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — PNTG or SGRY?
By revenue growth (latest reported year), The Pennant Group, Inc.
(PNTG) is pulling ahead at 36. 3% versus 6. 2% for Surgery Partners, Inc. (SGRY). On earnings-per-share growth, the picture is similar: Surgery Partners, Inc. grew EPS 54. 1% year-over-year, compared to 18. 3% for The Pennant Group, Inc.. Over a 3-year CAGR, PNTG leads at 26. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — PNTG or SGRY?
The Pennant Group, Inc.
(PNTG) is the more profitable company, earning 3. 1% net margin versus -2. 4% for Surgery Partners, Inc. — meaning it keeps 3. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SGRY leads at 11. 8% versus 5. 4% for PNTG. At the gross margin level — before operating expenses — SGRY leads at 23. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is PNTG or SGRY more undervalued right now?
On forward earnings alone, The Pennant Group, Inc.
(PNTG) trades at 24. 6x forward P/E versus 38. 7x for Surgery Partners, Inc. — 14. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SGRY: 27. 5% to $18. 60.
08Which pays a better dividend — PNTG or SGRY?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is PNTG or SGRY better for a retirement portfolio?
For long-horizon retirement investors, The Pennant Group, Inc.
(PNTG) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 79), +115. 6% 10Y return). Both have compounded well over 10 years (PNTG: +115. 6%, SGRY: +4. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between PNTG and SGRY?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: PNTG is a small-cap high-growth stock; SGRY is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.